Chesapeake Clinical Research, Inc. | White Marsh, MD

Research site

About

High level, experienced asthma/allergy/immunology site. Extensive experience in asthma, sinusitis, nasal polyposis, allergic rhinitis, eosinophilic disorders, urticaria and atopic dermatitis. We also work on vaccine trials and respiratory viral diseases.

Location

5430 Campbell Boulevard Suite #110, White Marsh, Maryland, United States of America

Site insights

Top conditions

Top treatments

Verekitug

UPB-101

Gefapixant

PF-04965842

MK-7264

CDX-0159

Rocatinlimab

BAY1817080

DUPIXENT®

MK-7264-043

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Contact this site

Jonathan Matz

Verified by this site

Active trials

7 of 25 total trials

A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)

The primary purpose of this study is to evaluate the long-term safety and efficacy of verekitug (UPB-101) in participants who complete the VALIANT st...

Enrolling

Severe Asthma

Drug: Verekitug

Drug: Placebo

A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma

The primary objective of this study is to describe the efficacy of rocatinlimab in reducing asthma exacerbations.

Enrolling

Asthma

Drug: Placebo

Drug: Rocatinlimab

A Study of Lebrikizumab (LY3650150) in Adult Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)

The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with chronic rhinosinusitis and nasal pol...

Enrolling

Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

Drug: Standard therapy for INCS

Drug: LY3650150

A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)

The purpose of this study is to evaluate the efficacy and safety of verekitug (UPB-101) in participants with severe asthma. The study will evaluate t...

Active, not recruiting

Severe Asthma

Drug: Placebo

Drug: Verekitug (UPB-101)

Rademikibart Add-on Treatment of an Acute Asthma Exacerbation (Seabreeze STAT Asthma)

This is a Phase 2, randomized, multicenter study in adult and adolescent participants with asthma and type 2 inflammation

Enrolling

Asthma Acute

Combination Product: Rademikibart in prefilled syringe

Drug: Matching placebo in prefilled syringe

Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)

This is a 2-part, proof-of-concept study to be conducted globally, designed to evaluate the safety, tolerability, clinical activity, pharmacokinetics...

Enrolling

Chronic Inducible Urticaria

Chronic Spontaneous Urticaria

Drug: Placebo

Drug: BLU-808

Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis (JADE EXTEND)

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...

Active, not recruiting

Dermatitis, Atopic

Drug: Abrocitinib 200 mg

Drug: Abrocitinib 100 mg